Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,233

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

Open access
Galimberti, Viviana, Cole, Bernard F, Zurrida, Stefano, Viale, Giuseppe, Luini, Alberto, Veronesi, Paolo, Baratella, Paola, Chifu, Camelia, Sargenti, Manuela, Intra, Mattia, Gentilini, Oreste, Mastropasqua, Mauro G, Mazzarol, Giovanni, Massarut, Samuele, Garbay, Jean-Rémi, Zgajnar, Janez, Galatius, Hanne, Recalcati, Angelo, Littlejohn, David, Bamert, Monika, Colleoni, Marco, Price, Karen N, Regan, Meredith M, Goldhirsch, Aron, Coates, Alan S, Gelber, Richard D, Veronesi, Umberto·2013·The Lancet Oncology

Abstract

Background For breast cancer patients with a metastatic sentinel node (SN), axillary dissection (AD) has been standard treatment. However, for patients with minimal SN involvement, AD may be overtreatment. IBCSG Trial 23-01 was designed to determine whether no AD is non-inferior to AD in patients with one or more micrometastatic (≤2 mm) SNs and tumour ≤5 cm. Methods In this multicentre trial patients were randomised to AD or no AD. Eligibility was limited to patients with clinically-palpable axillary lymph node(s) and a primary tumour ≤ 5 cm who, after sentinel node biopsy, had one or more micrometastatic (≤ 2 mm) sentinel lymphs nodes with no extracapsular extension. The primary endpoint was disease-free survival (DFS). Non-inferiority was defined as a hazard ratio of <1·25 for no AD vs. AD. The analysis was intention to treat. Patients were randomly allocated in a 1:1 ratio to AD or no AD with stratification by centre and menopausal status. There was no attempt to blind the treatment assignment. The trial is registered with ClinicalTrials.gov, NCT00072293. Per protocol, disease and survival information continues to be collected yearly. Findings From 2001 to 2010, 934 patients were randomised; 931 were evaluable (464 in the AD group and 467 in the no AD group). After a median follow-up of 5·0 (IQR 3.6–7.3) years, there were 124 DFS events, including breast-cancer-related events in 95 patients (local, 18; contralateral breast, 12; regional, 6; and distant, 59), and other events in 29 (second malignancy, 26; death without prior cancer event, 3). Five-year DFS was 87·8% (95% CI 84·4%–91·2%) in the no AD group and 84·4% (95% CI 80·7%–88·1%) in the AD group (log-rank p=0·16) (HR no AD vs. AD=0·78, 95% CI 0·55–1·11, non-inferiority p=0·0042). Patients with reported long-term surgical events (grade 3–4) included 1 sensory neuropathy (grade 3), 3 lymphedema (2 grade 3 and 1 grade 4), and 3 motor neuropathy (grade 3), all in the AD group, and 1 grade 3 motor neuropathy in the no AD group. One serious adverse event was reported, a post-operative infection in the axilla in the AD group. Interpretation AD in patients with early breast cancer represented in this study (most had tumours < 3 cm (92%; 856/931), received breast conserving surgery (91%; 845/931) and adjuvant systemic therapy (96%; 892/931)) should be avoided when the SN is minimally involved, thus eliminating complications of axillary surgery with no adverse effect on survival. Funding Supported in part: local participating centres, IBCSG central funds, CA075362 from the U.S. National Cancer Institute, and Swiss Cancer League/Cancer Research- Switzerland/Oncosuisse (ICPOCS 01688-03-2005). No pharmaceutical company funds were used.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(13)70035-4

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 1,233

Metadata

Authors
Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., Gentilini, O., Mastropasqua, M. G., Mazzarol, G., Massarut, S., Garbay, J.-R., Zgajnar, J., Galatius, H., Recalcati, A., Littlejohn, D., Bamert, M., Colleoni, M., Price, K. N., Regan, M. M., Goldhirsch, A., Coates, A. S., Gelber, R. D., & Veronesi, U.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2013-04
Volume
14
Issue
4
Pages
297-305
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2114794378
Cited by
1,233
References
23
FWCI
39.42
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(13)70035-4
The paper
Galimberti, V., Cole, B. F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., Gentilini, O., Mastropasqua, M. G., Mazzarol, G., Massarut, S., Garbay, J.-R., Zgajnar, J., Galatius, H., Recalcati, A., Littlejohn, D., . . . Veronesi, U. (2013). Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(13)70035-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.